Transcept Pharmaceuticals, Inc. (Nasdaq:

) today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval of Intermezzo® for use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. Transcept expects that the Intermezzo® NDA resubmission, if accepted and deemed complete by the FDA, will be subject to a Class 2 six-month review.